DBV Technologies (DBVT) Cash from Financing Activities (2020 - 2026)
DBV Technologies (DBVT) posted Cash from Financing Activities of $100000.0 for Q2 2026, down 99.89% sequentially from $88.9 million in Q1 2026, and down 99.91% YoY from $117.0 million in Q2 2025.
DBV Technologies (DBVT) Cash from Financing Activities (2020 - 2026) Analysis & Trends
DBV Technologies has reported Cash from Financing Activities for 7 years, with the latest figure at $100000.0 in Q2 2026.
- Quarterly Cash from Financing Activities fell 99.91% year-over-year to $100000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $248.2 million (up 110.89% YoY) and the FY2025 annual result came in at $276.2 million, up 46949.74% from the prior year.
- Cash from Financing Activities slipped to $100000.0 in Q2 2026 per DBVT's latest filing, from $88.9 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $195.4 million in Q2 2022 and troughed at -$837000.0 in Q3 2023.
- A 5-year average of $33.3 million and a median of $7000.0 in 2024 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities sank 342.86% in 2024, then soared 354645.45% in 2025.
- Over 5 years, Cash from Financing Activities stood at -$283000.0 in 2022, then jumped by 33.22% to -$189000.0 in 2023, then soared by 457.14% to $675000.0 in 2024, then soared by 23464.44% to $159.1 million in 2025, then tumbled by 99.94% to $100000.0 in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $100000.0, $88.9 million, and $159.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | DBV Technologies | 6.08 Bn | 5.90 Bn | - | 100,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 100,000.00 |
| Jun 30, 2026 | 100,000.00 |
| Mar 31, 2026 | 88.90 Mn |
| Mar 31, 2026 | 88.90 Mn |
| Dec 31, 2025 | 159.06 Mn |
| Dec 31, 2025 | 159.06 Mn |
| Sep 30, 2025 | 122,000.00 |
| Sep 30, 2025 | 122,000.00 |
| Jun 30, 2025 | 117.00 Mn |
| Jun 30, 2025 | 117.00 Mn |
| Dec 31, 2024 | 675,000.00 |
| Dec 31, 2024 | 675,000.00 |
| Sep 30, 2024 | 7,000.00 |
| Sep 30, 2024 | 7,000.00 |
| Jun 30, 2024 | -33,000.00 |
| Jun 30, 2024 | -33,000.00 |
| Mar 31, 2024 | -62,000.00 |
| Mar 31, 2024 | -62,000.00 |
| Dec 31, 2023 | -189,000.00 |
| Dec 31, 2023 | -189,000.00 |